<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34697451</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Loss of TDP-43 function underlies hippocampal and cortical synaptic deficits in TDP-43 proteinopathies.</ArticleTitle><Pagination><StartPage>931</StartPage><EndPage>945</EndPage><MedlinePgn>931-945</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-021-01346-0</ELocationID><Abstract><AbstractText>TDP-43 proteinopathy is linked to neurodegenerative diseases that feature synaptic loss in the cortex and hippocampus, although it remains unclear how TDP-43 regulates mature synapses. We report that, in adult mouse hippocampus, TDP-43 knockdown, but not overexpression, induces robust structural and functional damage to excitatory synapses, supporting a role for TDP-43 in maintaining mature synapses. Dendritic spine loss induced by TDP-43 knockdown is rescued by wild-type TDP-43, but not ALS/FTLD-associated mutants, suggesting a common TDP-43 functional deficiency in neurodegenerative diseases. Interestingly, M337V and A90V mutants also display dominant negative activities against WT TDP-43, partially explaining why M337V transgenic mice develop hippocampal degeneration similar to that in excitatory neuronal TDP-43 knockout mice, and why A90V mutation is associated with Alzheimer's disease. Further analyses reveal that a TDP-43 knockdown-induced reduction in GluN2A contributes to synaptic loss. Our results show that loss of TDP-43 function underlies hippocampal and cortical synaptic degeneration in TDP-43 proteinopathies.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ni</LastName><ForeName>Jiangxia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ren</LastName><ForeName>Yongfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Tonghui</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Chaoying</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>De'an</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6377-1281</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yaoyang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5363-9834</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yanshan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-4123-0174</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3886-0204</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China. gengyang@sioc.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yelin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9793-2941</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No.100 Haike Rd. Pudong New District, Shanghai, 201210, China. chenyelin@sioc.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34697451</ArticleId><ArticleId IdType="doi">10.1038/s41380-021-01346-0</ArticleId><ArticleId IdType="pii">10.1038/s41380-021-01346-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen-Plotkin AS, Lee VM-Y, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010;6:211&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.18</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM-Y, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2012;13:38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Shorter J. Biology and pathobiology of TDP-43 and emergent therapeutic strategies. Cold Spring Harb Perspect Med. 2017;7:a024554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024554</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Lee VM, Trojanowski JQ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011;17:659&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Neumann M, Sampathu DM, Lee VM-Y, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0226-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM-Y. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol. 2007;64:1388&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.10.1388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Uryu K, Trojanowski JQ, Lee VM-Y. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals. 2008;16:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109758</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv Genet. 2015;91:1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Oiwa K, Murata Y, Komine O, Sobue A, Endo F, et al. ALS-linked TDP-43 M337V knock-in mice exhibit splicing deregulation without neurodegeneration. Mol Brain. 2020;13:8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010;19:671&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Yang C. TDP-43&#x2014;The key to understanding amyotrophic lateral sclerosis. Rare Dis. 2014;2:e944443.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21675511.2014.944443</ArticleId></ArticleIdList></Reference><Reference><Citation>Broeck LV, Callaerts P, Dermaut B. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis? Trends Mol Med. 2014;20:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2013.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-S, Cheng W-C, Chen C-Y, Wu M-C, Wang Y-C, Tseng Y-H, et al. Transcriptomopathies of pre-and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol Commun. 2019;7:50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0674-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R, et al. Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathol. 2015;129:53&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1358-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol. 2016;131:571&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AC, Dugger BN, Dickson DW, Wang D-S. TDP-43 in aging and Alzheimer&#x2019;s disease-a review. Int J Clin. 2011;4:147.</Citation></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:811&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Bettens K, Gijselinck I, Engelborghs S, Pickut BA, Van Miegroet H, et al. Contribution of TARDBP to Alzheimer&#x2019;s disease genetic etiology. J Alzheimer&#x2019;s Dis. 2010;21:423&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100198</ArticleId></ArticleIdList></Reference><Reference><Citation>Broeck LV, Kleinberger G, Chapuis J, Gistelinck M, Amouyel P, Van Broeckhoven C, et al. Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. Neurobiol Aging. 2015;36:1121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Wils H, Kleinberger G, Joris G, Cuijt I, Ceuterick-de Groote C, et al. Overexpression of ALS-associated p. M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol. 2013;48:22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8427-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2009;106:18809&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling S-C, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci USA. 2013;110:E736&#x2013;E745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1074069</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous &#x3b1;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.08.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in &#x3b1;-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1091-10.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer&#x2019;s disease. Mol Neurobiol. 2008;37:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-008-8018-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14:401&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3505</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Hartmann H, Serdaroglu A, Schludi MH, Hornburg D, Meissner F, et al. TDP&#x2010;43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO J. 2016;35:2350&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Ferris J, Gao F-B. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol Brain. 2009;2:30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-2-30</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog JJ, Deshpande M, Shapiro L, Rodal AA, Paradis S. TDP-43 misexpression causes defects in dendritic growth. Sci Rep. 2017;7:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-15914-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog JJ, Xu W, Deshpande M, Rahman R, Suib H, Rodal AA, et al. TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression. Proc Natl Acad Sci USA. 2020;117:11760&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1917038117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang Y, Ert&#xfc;rk A, Kallop D, Jiang Z, Weimer RM, et al. Activity-induced Nr4a1 regulates spine density and distribution pattern of excitatory synapses in pyramidal neurons. Neuron. 2014;83:431&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.05.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1068999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois-Moutal L, Perez-Miller S, Scott DD, Miranda V, Mollasalehi N, Khanna M. Structural insights into TDP-43 proteinopathy. Front Mol Neurosci. 2019;12:301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00301</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Van, Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD&#x2013;ALS spectrum disorders. Hum Mol Genet. 2013;22:R77&#x2013;R87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt349</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GS, Watanabe TF, Amporndanai K, Plotkin SS, Cashman NR, Antonyuk SV, et al. Purification and structural characterization of aggregation-prone human TDP-43 involved in neurodegenerative diseases. Iscience. 2020;23:101159.</Citation></Reference><Reference><Citation>Pesiridis GS, Lee VM-Y, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet. 2009;18:R156&#x2013;R162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp303</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Caulfield T, Xu Y-F, Gendron TF, Hubbard J, Stetler C, et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet. 2013;22:3112&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, Chew J, Xu Y-F, Gendron TF, Garrett A, Lee CW, et al. The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo. Brain Res. 2016;1647:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.069</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Sivakumar P, Humphrey J, Lo K, Ricketts T, Oliveira H, et al. Mice with endogenous TDP&#x2010;43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37:e98684.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, San Juan IG, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed ZE, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson E, Breckenridge L, McMahon L, Som S, McConnell I, Bloom GS. Extracellular tau oligomers induce invasion of endogenous tau into the somatodendritic compartment and axonal transport dysfunction. J Alzheimer&#x2019;s Dis. 2017;58:803&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170168</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:552&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem cortex samples identify distinct molecular subtypes of als: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 2019;29:1164&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.09.066</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder P, Chu J-F, Chatterjee B, Swamy KB, Shen C-KJ. Co-regulation of mRNA translation by TDP-43 and Fragile X Syndrome protein FMRP. Acta Neuropathol. 2016;132:721&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1603-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M, Feiguin F, Buratti E. TBPH/TDP-43 modulates translation of Drosophila futsch mRNA through an UG-rich sequence within its 5&#x2032; UTR. Brain Res. 2016;1647:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.02.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelagandan N, Gonnella G, Dang S, Janiesch PC, Miller KK, K&#xfc;chler K, et al. TDP-43 enhances translation of specific mRNAs linked to neurodegenerative disease. Nucleic Acids Res. 2019;47:341&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky972</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9:1104&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr901076y</ArticleId></ArticleIdList></Reference><Reference><Citation>Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N. Differential expression of five N&#x2010;methyl&#x2010;D&#x2010;aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol. 1994;347:150&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903470112</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3504</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini L, Carrano N, Di Luca M, Gardoni F. Synaptic GluN2A-containing NMDA receptors: from physiology to pathological synaptic plasticity. Int J Mol Sci. 2020;21:1538.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041538</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, et al. Hippocampal sclerosis and TDP&#x2010;43 pathology in aging and A lzheimer disease. Ann Neurol. 2015;77:942&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24388</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain Res. 2019;142:1503&#x2013;27.</Citation></Reference><Reference><Citation>Winton MJ, Van Deerlin VM, Kwong LK, Yuan W, Wood EM, Yu C-E, et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett. 2008;582:2252&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.05.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Almeida S, Lu Y, Nishimura AL, Peng L, Sun D, et al. Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One. 2013;8:e76055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076055</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553c88</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Kaneko K, Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J Biol Chem. 2013;288:3641&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Hou SC, Yan YT, Jiang ST, Shen CKJ. TDP&#x2010;43, a neuro&#x2010;pathosignature factor, is essential for early mouse embryogenesis. Genesis. 2010;48:56&#x2013;62.</Citation></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP knockin mouse model of ALS. Cell Rep. 2019;26:364&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprengel R, Suchanek B, Amico C, Brusa R, Burnashev N, Rozov A, et al. Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. Cell. 1998;92:279&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80921-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Martel M-A, Ryan TJ, Bell KFS, Fowler JH, McMahon A, Al-Mubarak B, et al. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron. 2012;74:543&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Clemente A, Nicoll RA, Roche KW. Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist. 2013;19:62&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858411435129</ArticleId></ArticleIdList></Reference><Reference><Citation>Barria A, Malinow R. NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII. Neuron. 2005;48:289&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.08.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Punnakkal P, Jendritza P, K&#xf6;hr GJN. Influence of the intracellular GluN2 C-terminal domain on NMDA receptor function. Neuropharmacology. 2012;62: 1985&#x2013;92.</Citation></Reference><Reference><Citation>Hackos DH, Lupardus PJ, Grand T, Chen Y, Wang T-M, Reynen P, et al. Positive allosteric modulators of GluN2A-containing NMDARs with distinct modes of action and impacts on circuit function. Neuron. 2016;89:983&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Su T, Lu Y, Geng Y, Lu W, Chen Y. How could N-methyl-D-aspartate receptor antagonists lead to excitation instead of inhibition? Brain Sci Adv. 2018;4:73&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="doi">10.26599/BSA.2018.2018.9050009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>